Navigation Links
Qualyst Transporter Solutions, LLC Announces Launch of New FDA Services Offering
Date:6/26/2012

RESEARCH TRIANGLE PARK, N.C., June 26, 2012 /PRNewswire-iReach/ -- Qualyst Transporter Solutions, LLC has launched a contract service offering using a clinically-relevant model to assess FDA concerns on drug transporter related hepatic drug-drug interactions.  The newest FDA draft guidance on drug interactions (February, 2012) specifies six hepatic drug transporters of interest, which include three uptake and three efflux transport proteins.

"What is missing in the market is a way to address FDA concerns around transporter-based drug interactions that is predictive of an in vivo outcome." said Dr. Christopher Black, CEO for Qualyst Transporter Solutions.  "Utilizing the gold-standard sandwich-culture hepatocyte model, we have applied our clinically-relevant B-CLEAR® technology in order to produce a cost-effective answer to the FDA's concerns," said Dr. Black.

Many of the ways that current technologies try to address the FDA concerns involve in vitro transfected systems.  Data from these systems are difficult to translate into reliable in vivo knowledge. An integrated in vitro system, like hepatocytes, with multiple localized, functioning, and expressed uptake and efflux transporters, is required to accurately predict and describe in vivo transporter-based drug interactions.

Experiments can be performed in hepatocytes from multiple species, including humans, and the streamlined results are provided as a percent change from control.  Clinically relevant positive controls are included in order to gauge the relative inhibitory potency of the tested compounds.  Qualyst Transporter Solutions has a large historical data base which can help provide clinical perspective on the effects of your compound for an FDA submission.   This can be important since many models overestimate inhibitory interactions or there may be inhibitory effects on a single transporter that can be compensated for by other transporters.  You need an integrated system to evaluate this.  "Because we have hundreds of studies and years of experience with a variety of compound behavior, we can provide perspective to results that is difficult to get anywhere else and critical for the FDA," said Dr. Kenneth Brouwer, CSO.

Qualyst Transporter Solutions only uses Transporter Certified™ hepatocytes and clinically-relevant probe substrates along with positive control inhibitors to examine the potential for in vivo relevant transporter-based drug interactions.  The key to obtaining in vivo-relevant answers is to use a fully integrated, functioning cell system that has been certified.  "We certify our hepatocytes to ensure a fully functioning complement of uptake and efflux transporters, which guarantees that the results are in vivo-relevant," said Dr. Brouwer.

About Qualyst Transporter Solutions, LLC

Qualyst Transporter Solutions commercializes novel and proprietary drug transport and hepatobiliary disposition products for drug discovery and development.  Qualyst Transporter Solutions products provide answers to transporter questions that arise in drug discovery and development.  For additional information, please refer to the company's web site at www.qualyst.com or call (919) 313-6500.

Media Contact: Christopher Black Qualyst Transporter Solutions, LLC, 919-297-8681, chrisblack@qualyst.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

 


'/>"/>
SOURCE Qualyst Transporter Solutions, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Chandler Chicco Companies Acquires Haas & Health Partner Public Relations and SanCom Creative Communication Solutions, Creating Unrivalled Healthcare Communication Capability in Germany
2. Amarillo Biosciences Announces Plan to Open Asia Operations Center in Taipei, Taiwan
3. Bronstein, Gewirtz & Grossman, LLC Announces Investigation of American Oriental Bioengineering Inc.
4. Pacific BioStorage Announces an Exciting New First for The Life Sciences Industry in Southern California
5. JH Technologies Announces Launch of Their New Website
6. Cetero Research Announces Executive Appointments and New Company Name
7. American Botanical Council Announces New Publication "Herbal News & Events"
8. SEE ALGAE Technology GmbH Announces Sale of Algae Farm to Brazils Grupo JB
9. 5AM Solutions Announces Release of the Ion AmpliSeq™ Designer v1.2
10. Kitware Announces Opening of Santa Fe Office
11. Keryx Biopharmaceuticals Announces Live Webcast of Upcoming Analyst Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... the pharmaceutical and biotechnology industries to improve patient outcomes and quality of life, ... in analytical testing are being attributed to new regulatory requirements for all new ...
(Date:10/11/2017)... ... October 11, 2017 , ... The CRISPR-Cas9 ... overexpression experiments and avoiding the use of exogenous expression plasmids. The simplicity of ... performing systematic gain-of-function studies. , This complement to loss-of-function studies, such as ...
(Date:10/11/2017)... ... 11, 2017 , ... Proscia Inc ., a data ... titled, “Pathology is going digital. Is your lab ready?” with Dr. Nicolas Cacciabeve, ... and how Proscia improves lab economics and realizes an increase in diagnostic confidence.* ...
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased ... of over 5.5 million people each year. Especially those living in larger cities are ... - based in one of the most pollution-affected countries globally - decided to take ...
Breaking Biology Technology:
(Date:4/5/2017)... LONDON , April 4, 2017 KEY ... is anticipated to expand at a CAGR of 25.76% ... neurodegenerative diseases is the primary factor for the growth ... full report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The ... of product, technology, application, and geography. The stem cell ...
(Date:3/30/2017)... 30, 2017 The research team of The ... (3D) fingerprint identification by adopting ground breaking 3D fingerprint minutiae recovery ... of speed and accuracy for use in identification, crime investigation, immigration ... ... A research team ...
(Date:3/27/2017)... CENTRE, N.Y. , March 27, 2017 /PRNewswire-USNewswire/ ... Healthcare Information and Management Systems Society (HIMSS) Analytics ... Outpatient EMR Adoption Model sm . In addition, ... 12% of U.S. hospitals using an electronic medical ... CHS for its high level of EMR usage ...
Breaking Biology News(10 mins):